Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
30
VNRX Quote, Financials, Valuation and Earnings
Last price:
$0.28
Seasonality move
:
-3.86%
Day range:
$0.27 - $0.28
52-week range:
$0.22 - $0.94
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
18.97x
P/B ratio:
--
Volume:
992.7K
Avg. volume:
2.9M
1-year change:
-56.68%
Market cap:
$34M
Revenue:
$1.2M
EPS (TTM):
-$0.23
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
VNRX
VolitionRX Ltd.
|
$714.1K | -$0.04 | 272.5% | -33.67% | $2.20 |
|
CATX
Perspective Therapeutics, Inc.
|
$231.1K | -$0.35 | -9.65% | -37.91% | $12.3077 |
|
INFU
InfuSystem Holdings, Inc.
|
$36.7M | $0.05 | 8.36% | 39.86% | $14.20 |
|
PMI
Picard Medical
|
-- | -- | -- | -- | -- |
|
VTAK
Catheter Precision, Inc.
|
$310K | -$0.20 | 118.75% | -11.57% | -- |
|
XTNT
Xtant Medical Holdings, Inc.
|
$30.8M | -- | -2.42% | -100% | $1.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
VNRX
VolitionRX Ltd.
|
$0.28 | $2.20 | $34M | -- | $0.00 | 0% | 18.97x |
|
CATX
Perspective Therapeutics, Inc.
|
$2.8100 | $12.3077 | $208.9M | -- | $0.00 | 0% | 190.53x |
|
INFU
InfuSystem Holdings, Inc.
|
$8.77 | $14.20 | $178.3M | 33.54x | $0.00 | 0% | 1.32x |
|
PMI
Picard Medical
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
VTAK
Catheter Precision, Inc.
|
$2.01 | -- | $2.5M | 0.40x | $0.00 | 0% | 9.45x |
|
XTNT
Xtant Medical Holdings, Inc.
|
$0.71 | $1.50 | $99.4M | 69.62x | $0.00 | 0% | 0.78x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
VNRX
VolitionRX Ltd.
|
-48.16% | 2.723 | 15.4% | 0.04x |
|
CATX
Perspective Therapeutics, Inc.
|
1.35% | 3.042 | 1.3% | 8.47x |
|
INFU
InfuSystem Holdings, Inc.
|
30.8% | 4.042 | 11.73% | 1.35x |
|
PMI
Picard Medical
|
-- | 0.000 | -- | -- |
|
VTAK
Catheter Precision, Inc.
|
68.63% | 0.156 | 537.37% | 0.41x |
|
XTNT
Xtant Medical Holdings, Inc.
|
39.2% | 3.120 | 35.76% | 1.08x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
VNRX
VolitionRX Ltd.
|
$318.2K | -$5.1M | -- | -- | -813.17% | -$3.5M |
|
CATX
Perspective Therapeutics, Inc.
|
-$566K | -$27.9M | -37.13% | -37.63% | -13330.62% | -$18.3M |
|
INFU
InfuSystem Holdings, Inc.
|
$20.3M | $3.8M | 6.43% | 9.93% | 10.45% | $8.4M |
|
PMI
Picard Medical
|
-- | -- | -- | -- | -- | -- |
|
VTAK
Catheter Precision, Inc.
|
-$320K | -$3M | -79.27% | -192.05% | -1336.73% | -$2.2M |
|
XTNT
Xtant Medical Holdings, Inc.
|
$22M | $2.5M | 2.15% | 3.78% | 7.64% | $4.2M |
VolitionRX Ltd. vs. Competitors
-
Which has Higher Returns VNRX or CATX?
Perspective Therapeutics, Inc. has a net margin of -862.39% compared to VolitionRX Ltd.'s net margin of -12425.36%. VolitionRX Ltd.'s return on equity of -- beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.
Company Gross Margin Earnings Per Share Invested Capital VNRXVolitionRX Ltd.50.73% -$0.05 -$24.7M CATXPerspective Therapeutics, Inc.-270.81% -$0.35 $245.5M -
What do Analysts Say About VNRX or CATX?
VolitionRX Ltd. has a consensus price target of $2.20, signalling upside risk potential of 694.8%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 338%. Given that VolitionRX Ltd. has higher upside potential than Perspective Therapeutics, Inc., analysts believe VolitionRX Ltd. is more attractive than Perspective Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VNRXVolitionRX Ltd.4 2 0 CATXPerspective Therapeutics, Inc.12 1 0 -
Is VNRX or CATX More Risky?
VolitionRX Ltd. has a beta of 1.234, which suggesting that the stock is 23.404% more volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.182, suggesting its more volatile than the S&P 500 by 18.151%.
-
Which is a Better Dividend Stock VNRX or CATX?
VolitionRX Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. VolitionRX Ltd. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VNRX or CATX?
VolitionRX Ltd. quarterly revenues are $627.3K, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. VolitionRX Ltd.'s net income of -$5.4M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, VolitionRX Ltd.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for VolitionRX Ltd. is 18.97x versus 190.53x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VNRXVolitionRX Ltd.18.97x -- $627.3K -$5.4M CATXPerspective Therapeutics, Inc.190.53x -- $209K -$26M
-
Which has Higher Returns VNRX or INFU?
InfuSystem Holdings, Inc. has a net margin of -862.39% compared to VolitionRX Ltd.'s net margin of 6.19%. VolitionRX Ltd.'s return on equity of -- beat InfuSystem Holdings, Inc.'s return on equity of 9.93%.
Company Gross Margin Earnings Per Share Invested Capital VNRXVolitionRX Ltd.50.73% -$0.05 -$24.7M INFUInfuSystem Holdings, Inc.55.65% $0.11 $80.2M -
What do Analysts Say About VNRX or INFU?
VolitionRX Ltd. has a consensus price target of $2.20, signalling upside risk potential of 694.8%. On the other hand InfuSystem Holdings, Inc. has an analysts' consensus of $14.20 which suggests that it could grow by 61.92%. Given that VolitionRX Ltd. has higher upside potential than InfuSystem Holdings, Inc., analysts believe VolitionRX Ltd. is more attractive than InfuSystem Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VNRXVolitionRX Ltd.4 2 0 INFUInfuSystem Holdings, Inc.5 0 0 -
Is VNRX or INFU More Risky?
VolitionRX Ltd. has a beta of 1.234, which suggesting that the stock is 23.404% more volatile than S&P 500. In comparison InfuSystem Holdings, Inc. has a beta of 1.680, suggesting its more volatile than the S&P 500 by 68.01%.
-
Which is a Better Dividend Stock VNRX or INFU?
VolitionRX Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystem Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. VolitionRX Ltd. pays -- of its earnings as a dividend. InfuSystem Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VNRX or INFU?
VolitionRX Ltd. quarterly revenues are $627.3K, which are smaller than InfuSystem Holdings, Inc. quarterly revenues of $36.5M. VolitionRX Ltd.'s net income of -$5.4M is lower than InfuSystem Holdings, Inc.'s net income of $2.3M. Notably, VolitionRX Ltd.'s price-to-earnings ratio is -- while InfuSystem Holdings, Inc.'s PE ratio is 33.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for VolitionRX Ltd. is 18.97x versus 1.32x for InfuSystem Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VNRXVolitionRX Ltd.18.97x -- $627.3K -$5.4M INFUInfuSystem Holdings, Inc.1.32x 33.54x $36.5M $2.3M
-
Which has Higher Returns VNRX or PMI?
Picard Medical has a net margin of -862.39% compared to VolitionRX Ltd.'s net margin of --. VolitionRX Ltd.'s return on equity of -- beat Picard Medical's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital VNRXVolitionRX Ltd.50.73% -$0.05 -$24.7M PMIPicard Medical-- -- -- -
What do Analysts Say About VNRX or PMI?
VolitionRX Ltd. has a consensus price target of $2.20, signalling upside risk potential of 694.8%. On the other hand Picard Medical has an analysts' consensus of -- which suggests that it could fall by --. Given that VolitionRX Ltd. has higher upside potential than Picard Medical, analysts believe VolitionRX Ltd. is more attractive than Picard Medical.
Company Buy Ratings Hold Ratings Sell Ratings VNRXVolitionRX Ltd.4 2 0 PMIPicard Medical0 0 0 -
Is VNRX or PMI More Risky?
VolitionRX Ltd. has a beta of 1.234, which suggesting that the stock is 23.404% more volatile than S&P 500. In comparison Picard Medical has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock VNRX or PMI?
VolitionRX Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Picard Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. VolitionRX Ltd. pays -- of its earnings as a dividend. Picard Medical pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VNRX or PMI?
VolitionRX Ltd. quarterly revenues are $627.3K, which are larger than Picard Medical quarterly revenues of --. VolitionRX Ltd.'s net income of -$5.4M is higher than Picard Medical's net income of --. Notably, VolitionRX Ltd.'s price-to-earnings ratio is -- while Picard Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for VolitionRX Ltd. is 18.97x versus -- for Picard Medical. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VNRXVolitionRX Ltd.18.97x -- $627.3K -$5.4M PMIPicard Medical-- -- -- --
-
Which has Higher Returns VNRX or VTAK?
Catheter Precision, Inc. has a net margin of -862.39% compared to VolitionRX Ltd.'s net margin of -1037.17%. VolitionRX Ltd.'s return on equity of -- beat Catheter Precision, Inc.'s return on equity of -192.05%.
Company Gross Margin Earnings Per Share Invested Capital VNRXVolitionRX Ltd.50.73% -$0.05 -$24.7M VTAKCatheter Precision, Inc.-141.59% -$1.70 $21.3M -
What do Analysts Say About VNRX or VTAK?
VolitionRX Ltd. has a consensus price target of $2.20, signalling upside risk potential of 694.8%. On the other hand Catheter Precision, Inc. has an analysts' consensus of -- which suggests that it could grow by 1790.6%. Given that Catheter Precision, Inc. has higher upside potential than VolitionRX Ltd., analysts believe Catheter Precision, Inc. is more attractive than VolitionRX Ltd..
Company Buy Ratings Hold Ratings Sell Ratings VNRXVolitionRX Ltd.4 2 0 VTAKCatheter Precision, Inc.0 0 0 -
Is VNRX or VTAK More Risky?
VolitionRX Ltd. has a beta of 1.234, which suggesting that the stock is 23.404% more volatile than S&P 500. In comparison Catheter Precision, Inc. has a beta of -1.392, suggesting its less volatile than the S&P 500 by 239.195%.
-
Which is a Better Dividend Stock VNRX or VTAK?
VolitionRX Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. VolitionRX Ltd. pays -- of its earnings as a dividend. Catheter Precision, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VNRX or VTAK?
VolitionRX Ltd. quarterly revenues are $627.3K, which are larger than Catheter Precision, Inc. quarterly revenues of $226K. VolitionRX Ltd.'s net income of -$5.4M is lower than Catheter Precision, Inc.'s net income of -$2.3M. Notably, VolitionRX Ltd.'s price-to-earnings ratio is -- while Catheter Precision, Inc.'s PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for VolitionRX Ltd. is 18.97x versus 9.45x for Catheter Precision, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VNRXVolitionRX Ltd.18.97x -- $627.3K -$5.4M VTAKCatheter Precision, Inc.9.45x 0.40x $226K -$2.3M
-
Which has Higher Returns VNRX or XTNT?
Xtant Medical Holdings, Inc. has a net margin of -862.39% compared to VolitionRX Ltd.'s net margin of 3.93%. VolitionRX Ltd.'s return on equity of -- beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.
Company Gross Margin Earnings Per Share Invested Capital VNRXVolitionRX Ltd.50.73% -$0.05 -$24.7M XTNTXtant Medical Holdings, Inc.66.13% $0.01 $82.9M -
What do Analysts Say About VNRX or XTNT?
VolitionRX Ltd. has a consensus price target of $2.20, signalling upside risk potential of 694.8%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 111.24%. Given that VolitionRX Ltd. has higher upside potential than Xtant Medical Holdings, Inc., analysts believe VolitionRX Ltd. is more attractive than Xtant Medical Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VNRXVolitionRX Ltd.4 2 0 XTNTXtant Medical Holdings, Inc.2 0 0 -
Is VNRX or XTNT More Risky?
VolitionRX Ltd. has a beta of 1.234, which suggesting that the stock is 23.404% more volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.077, suggesting its less volatile than the S&P 500 by 107.701%.
-
Which is a Better Dividend Stock VNRX or XTNT?
VolitionRX Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. VolitionRX Ltd. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VNRX or XTNT?
VolitionRX Ltd. quarterly revenues are $627.3K, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. VolitionRX Ltd.'s net income of -$5.4M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, VolitionRX Ltd.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 69.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for VolitionRX Ltd. is 18.97x versus 0.78x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VNRXVolitionRX Ltd.18.97x -- $627.3K -$5.4M XTNTXtant Medical Holdings, Inc.0.78x 69.62x $33.3M $1.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
69
RGC alert for Jan 7
Regencell Bioscience Holdings Ltd. [RGC] is up 58.95% over the past day.
Buy
69
WDC alert for Jan 7
Western Digital Corp. [WDC] is down 8.88% over the past day.
Buy
75
DRUG alert for Jan 7
Bright Minds Biosciences, Inc. [DRUG] is up 2.99% over the past day.
